The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
In a prospective follow-up the outcome of 60 chronic schizophrenic patients who discontinued neuroleptic therapy after remaining stable 12-48 months was compared with controls continuing medication. Not only did the drug-discontinued patients have more relapses (P less than 0.001), but the form of relapse was both more severe and acute, resulting in differences of self-injury (P less than 0.05), anti-social behaviour (P less than 0.01), inpatient admissions (P less than 0.001), and the use of compulsory powers (P less than 0.01). In patients who relapsed, both social and work function was affected adversely for some months. Patients who remained relapse-free without drugs (20%) had a level of work and social function similar to medicated patients. At the end of 18 months the patients who discontinued depot maintenance therapy were found to have been prescribed one-third more neuroleptic drugs than controls, with a possible increase in the risk of long-term tardive dyskinesia.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D005475:Flupenthixol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005476:Fluphenazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012917:Social Adjustment; D013892:Thioxanthenes / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D013892:Thioxanthenes; C007761:flupenthixol decanoate; D005475:Flupenthixol; C011825:fluphenazine depot; D005476:Fluphenazine